Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.
about
Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosisVPAC receptors: structure, molecular pharmacology and interaction with accessory proteinsThe neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseasesThe role of microbiome in central nervous system disordersThe Second Brain: Is the Gut Microbiota a Link Between Obesity and Central Nervous System Disorders?Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels.VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy.Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease.Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses.Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis.Gut microbiome and the risk factors in central nervous system autoimmunity.VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Single nucleotide polymorphisms in the 3'UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p.Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis.Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population.Tuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersVIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repairEmerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agentsNeuropeptides as pleiotropic modulators of the immune response.Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.The effects of vasoactive intestinal peptide in neurodegenerative disorders.Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP.Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in miceChemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles.Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.Inhibition of JAK/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis.Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats.
P2860
Q24603606-780C1BA0-7B6D-415D-AEB2-0CB78F638906Q26827172-CECA2A8A-21C6-4D2D-BF19-9D569EDC4650Q26851670-74A6D614-BBFD-4A10-B055-43A24854AEEEQ28304749-EB45B3C7-DEFD-4C07-9713-401BD9F3EAA0Q30362129-BA055B58-7126-4CF6-A20E-71689741E2BFQ33652057-9955A221-FE9C-4705-9C65-6BF08BB3DCA1Q33712853-BE74FCF9-8498-4AC9-BBF0-084EC6912669Q33826520-2D499AE9-8559-4944-A65E-56792EFD1B2DQ33870752-A1B67974-68B9-4E78-A93D-D54906EEE081Q34222959-0FA46C82-401B-4E59-B908-02410D0EB413Q34238010-697FD652-A069-434F-BA09-DCC897A9F458Q34277527-4A0F340A-159C-4E3C-BFBA-BCC376673811Q34320335-7A21D196-75D5-40DD-BDFD-8FE976DDC617Q34624054-12465C06-ACC3-4A1F-B185-2D25CA862387Q34765538-293F50F1-2AA0-47BB-8F45-4C96065C76D9Q35295564-BC969471-E27D-43F5-9081-F04531A8EB98Q35414146-90E79484-8CB1-406A-8309-69D55A54DE78Q35799802-DE9666D8-2ED3-46A0-8DA0-CBE03D439FDBQ36153216-33BE12D5-ACDA-437E-B15A-3CAF91D4718CQ36499318-3ECD38C7-2284-49F3-853E-893008D09EABQ36764912-00ED7A24-BDB1-47AF-BD8A-4BD05DA8BED7Q36830470-2C337EA6-1FDB-4334-9EDE-C7051A58A687Q36929423-51A8B604-7AA7-4CE1-8160-44E456540F5AQ36969911-E4306385-6DF6-4F80-9B52-FDFA6BE35AD6Q37054934-F866FD3E-940A-4298-A861-C586CA1732DDQ37074087-501D8E08-9212-4947-82DD-F94FF681040BQ37100959-B3F090D0-C654-4002-A257-64C640BACD53Q37191369-B6F62C01-B53B-43E6-A6FB-E0D52816E109Q37206399-78C5D20F-68FE-41D0-A833-0D9E9B9EA622Q37898396-B98F812C-56D0-4482-B312-F2A99A1F363AQ38714704-3CA336F8-FEE7-440B-860D-57FBB589A6CAQ38992271-CBA62A17-8A67-4489-97D8-739AC4341449Q41884883-A15ADB0A-E857-4A61-A603-45499ED47984Q42754007-7489218B-9585-4FD9-B8D6-343DA6AE2A10Q43230806-223D872D-AA12-4823-BAAC-9CB4AFBE2EB1Q45882279-D73B947E-16B4-4AA9-83AF-F377BB2D6976Q47694093-3A1BA9BF-87EB-4FCD-9DBE-C69D1844F687Q51131975-10818B57-4782-4A51-A1FE-11E5AE284617Q54397909-307285AE-9725-4895-AB65-8CBEBD9C616C
P2860
Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@ast
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@en
type
label
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@ast
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@en
prefLabel
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@ast
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@en
P2860
P50
P1476
Therapeutic effect of vasoacti ...... tory and autoimmune responses.
@en
P2093
Amelia Fernandez-Martin
Doina Ganea
P2860
P304
P356
10.2353/AJPATH.2006.051081
P407
P577
2006-04-01T00:00:00Z